SynthesisFrontiers in endocrinology2026
Clinical parameters and emerging biomarkers of partial remission in pediatric type 1 diabetes: a systematic review.
Synthesis in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Explainable machine learning model for in-hospital hypoglycemia risk in patients with latent autoimmune diabetes in adults.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In type 1 diabetes (T1D), partial remission (PR) is a pivotal phase with preserved β-cell function, better glycemic stability, and reduced disease burden, and is as such a potential target for disease-modifying interventions. Identifying robust biomarkers of PR is critical for designing targeted therapies. This systematic review synthesizes current evidence from observational studies of biomarkers associated with PR in pediatric T1D. Methods: We searched the literature in PubMed, Scopus, and Embase (2009-2025), using strategies based on PICOS criteria. Investigated biomarkers covered multiple domains: anthropometric and clinical factors, continuous glucose monitoring metrics, HLA genotyping, immune cell and cytokine profiles, hormones, proteomics, and microRNAs. Eligible studies included observational cohorts of children and adolescents with newly diagnosed T1D. PR was defined as IDAA1c ≤9, HbA1c <7% with insulin requirement <0.5 IU/kg BW/day, or stimulated C-peptide ≥ 300pmol/L. Studies were selected according to PRISMA guidelines, and risk of bias was appraised using the Joanna Briggs Institute checklist. Results: Of 353 records, 39 studies including 9,368 patients met the inclusion criteria. Study populations ranged from 16 to 3,657 participants, with mean age of disease onset ranging from 7.0 to 13.8 years. Most studies (n=32) defined PR using IDAA1c. Routine clinical parameters and CGM-derived indices consistently distinguished remitters from non-remitters. Biological markers like immune signatures or proteomic profiles provided mechanistic insights into PR pathways. The methodological quality was moderate to high, though control of confounders and follow-up were incomplete. Conclusion: Standard-of-care biomarkers appear sufficient to identify PR and monitor its impact on glycemic outcomes. Emerging biological markers offer promising insights into the underlying mechanisms of PR. Well-powered studies are needed to clarify PR determinants and their therapeutic potential.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.